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pretest. RESULTS: With the author’s approval, the ques-
tionnaire was translated from English to French by two
independent translators. The two versions were compared
and a few non signiﬁcant differences were noted. The
translations were discussed and reviewed, item-by-item,
until a consensus was achieved: version 3. The version 3
was critically reviewed by a bilingual expert version 4. A
bilingual translator back-translated version 4 in version
4b which after discussion with the main author has been
accepted as expressing the questions in the same way as
the original version. CONCLUSION: To make sure that
the translation is consistent with our objective, the pretest
analysis is ongoing among 20 patients. For a large-scale
validation, this questionnaire will be remitted during a
clinical trial on a new therapeutic strategy in more than
80 patients.
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PSORIASIS AND ATOPIC DERMATITIS:
CROSS-DESCRIPTION OF PATIENTS’ QUALITY
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Skin diseases have a strong impact on the physical and
mental well-being of the patient. This is conﬁrmed by the
large number of quality of life studies that exist. Psoria-
sis and atopic dermatitis are the two most frequents
chronic dermatosis, therefore we estimated relevant to
cross-compare the patients’ quality of life. OBJECTIVES:
The Avène Dermatological Hydrotherapy Centre, which
welcomes over 2500 patients a year, offers real unity 
conditions of time and location in order to realise a 
cross-analysis. METHOD: A generic scale (SF-12) and a
speciﬁc scale (DLQI—Dermatology Life Quality Index)
are completed by each patient at their arrival at the Avène
Dermatological Hydrotherapy Centre. The completed
questionnaires were returned by post. RESULTS: In the
analysed population, the mean age is respectively 40.5
years old versus 55.5y.o. for patients suffering atopic der-
matitis (n = 141) versus psoriasis (n = 54) (p < 0.00001).
The DLQI score at inclusion is 37.84 for atopic dermati-
tis patients, 32.81 for psoriasis patients. Concerning the
SF-12, the results consisted of 2 scores: mental (MCS-12)
and physical (PCS-12). At inclusion the atopic dermatitis
patients scores were: PCS-12 = 47.5 & MCS-12 = 33.8,
the psoriasis patients scores were: PCS-12 = 46.3 & MCS-
12 = 39.0. If those two scales’ results show evidence of
an impairment in patients’ quality of life, no difference is
demonstrated between the two groups. CONCLUSION:
Those ﬁrst results demonstrated an equal impairment in
quality of life for patients suffering either from atopic 
dermatitis than psoriasis.
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Skin diseases have a strong impact on the physical and
mental well-being of the patient. This is conﬁrmed by the
large number of quality of life studies that exist. It is clear
that dermatological diseases affect not only the life of the
children but also that of his/her family. OBJECTIVES:
The Avène Dermatological Hydrotherapy Center, wel-
comes over 2500 patients a year suffering from skin 
diseases. The objective of the study is to demonstrate the
relevance of the long term effects of hydrotherapy treat-
ments on patients quality of life. METHOD: A generic
scale (SF-12) and a speciﬁc scale (DLQI—Dermatology
Life Quality Index) are completed by each patient at their
arrival at the Avène Dermatological Hydrotherapy Center
(inclusion), at the end of hydrotherapy cares (3 weeks)
and at 3 and 6 months. The completed questionnaires
were returned by post. RESULTS: In this ﬁrst analysis,
the ﬁrst 30 patients suffering from the three following
conditions: psoriasis, atopic dermatitis were taken into
account and analysed at inclusion and at the 6 months
after the hydrotherapy cares. The DLQI score at inclu-
sion is 32.1. At 6 months the DLQI score is 24.2. These
ﬁrst results show evidence of an improvement of patients’
quality of life 6 months after hydrotherapy treatments 
(p < 0.02). CONCLUSION: These ﬁrst results show evi-
dence of an improvement of patients’ quality of life 6
months after hydrotherapy treatments.
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OBJECTIVE: To evaluate the effect of psoriasis on
quality of life of patients in Spain. MEHOD: Four thou-
sand ﬁve hundred anonymous questionnaires (comprised
of two scales: the Psoriasis Disability Index (PDI) plus 10
questions concerning treatment and evolution of psoria-
sis) were sent, via a Psoriasis Patient Support Group
(AccionPsoriasis). RESULTS: Nineteen hundred ques-
tionnaires were returned (June 2002): response rate 42%.
An analysis of the ﬁrst 810 questionnaires was realised.
The sex ratio Men (M)/Women(W) was 49/51. Mean age:
42 years. Mean age of diagnosis: 21.8 years. The average
to the total score was 8.47 (s.d. 7.2 rank 0 to 39) i.e.
18.82 (s.d: 17.2) when reported to a scale of 0 to 100.
Signiﬁcative difference was observed between M and W
for the global handicap score 20.73 vs 16.95 p < 0.002.
Two groups was identiﬁed: pousée de psoriasis (84%),
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pas de poussée de psorisis (12%)—no answers (4%)—
Psoriasis had a greater adverse affect on patients with
crise: PDI score = 20.24 (sd 17.52) than the patient
without actual crise PDI score = 8.98 (sd 11.34). This dif-
ference was signiﬁcative p < 0.00001. CONCLUSION:
These results highlight the value of appropriate and rele-
vant psychological and medical environment for patients
suffering from psoriasis.
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DEVELOPMENT AND VALIDATION OF A
HEALTH-RELATED QUALITY OF LIFE
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OBJECTIVES: Melasma, a facial pigmentary condition
affecting women, can have signiﬁcant emotional and psy-
chological effects on those affected. Our purpose was 
to develop and validate a disease-speciﬁc HRQoL instru-
ment to identify the areas of the patient’s life most
impaired by melasma as well as the effects of the condi-
tion on their level of functioning in correlation with
disease severity, the Melasma Quality of Life scale
(MELASQOL). METHODS: A random sample of 102
women identiﬁed by an investigator as having melasma
were evaluated by the investigator using the Melasma
Area and Severity Index (MASI). The patients were then
anonymously surveyed with the SKINDEX-16, the Fear
of Negative Evaluation scale, the Dermatology Life
Quality Index (DLQI), a specially-developed skin dis-
coloration evaluation questionnaire, and a measure of
perceived life quality difference without melasma. The
10-item MELASQOL scale was devised from the 
comprehensive HRQoL assessment battery. RESULTS:
The psychometric properties of the MELASQOL were
comparable with the properties of the DLQI and the
SKINDEX-16. The MELASQOL scores were highly cor-
related with the other HRQoL measures. The discrimi-
natory ability of the MELASQOL is superior to the
SKINDEX-16 and the DLQI for melasma. The three life
domains most adversely affected by melasma (social life,
recreation/leisure, and emotional well-being) were high-
lighted by this instrument. These were the same three
areas of life that patients believed would improve the
most if they no longer were affected by the disease. CON-
CLUSION: The MELASQOL can be used to objectively
evaluate the effect of melasma on a patient’s HRQoL. The
high correlation with the DLQI, the SKINDEX-16, and
the skin discoloration questionnaire suggests that the new
scale is a valid instrument, which can be used to monitor
the level of impairment individuals suffer due to their
melasma.
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OBJECTIVE: To examine the effect of mail-based inter-
ventions on appropriate prescribing of COX-2 inhibitors
for patients at increased risk for adverse gastrointestinal
(GI) events. METHODS: The 600 highest-volume pre-
scribers of COX-2 inhibitors were identiﬁed from a health
plan database from October to December 2001, and 
randomly assigned to one of three intervention groups: 1)
High intervention (proﬁle incorporating probability of GI
bleed); 2) Medium intervention (pharmacy claim infor-
mation only; no probability modeling); and 3) No inter-
vention. Intervention physicians received monthly proﬁles
for 6 months (May 2002 through October 2002). Risk
factors used to calculate the probability of GI bleed
included: history of ulcer, arthritis, GI bleed, concurrent
use of anticoagulants or oral steroids, and age greater
than 65 years. Appropriate usage metrics were changes in
mean proportion of patients with each risk factor and
percentage of COX-2 inhibitor prescriptions out of all
anti-inﬂammatory medications. Proportions were com-
pared between intervention groups. Statistical analyses
were performed using multivariate Generalized Estimat-
ing Equations (GEE). RESULTS: Baseline proportions 
of COX-2 prescriptions for high intervention, medium
intervention, and no intervention groups were 0.602 ±
0.192, 0.603 ± 0.202, and 0.589 ± 0.202, respectively; 5-
month post-intervention proportions were 0.587 ± 0.269,
0.588 ± 0.253, and 0.619 ± 0.255, respectively; adjusted
GEE coefﬁcients were -0.048 (p = 0.001), -0.044 (p =
0.002), for the high and medium intervention groups,
respectively. Proportion of patients with a history of ulcer,
GI bleed, and arthritis also increased by 33%, 41%, and
26%, respectively, across all groups. However, differences
between groups were not signiﬁcant. CONCLUSIONS:
Preliminary analysis has shown a positive change in pre-
scribing patterns. First, there was a decrease in the pro-
portion of patients receiving COX-2 inhibitors. Second,
in patients receiving COX-2 inhibitors, the proportion of
patients with select risk factors (history of ulcer, GI bleed,
and arthritis) increased.
